冠状动脉慢血流与氧化应激的临床研究  

A clinical study on the relationship between coronary slow flow and oxidative stress

作　　者：闫丽英 张风雷 袁燕 张琦 徐新生 

机构地区：[1]山东省东营市人民医院急诊科,山东东营257091

出　　处：《临床心血管病杂志》2016年第4期351-354,共4页Journal of Clinical Cardiology

基　　金：山东省医药卫生科技发展计划项目(No:2013WS0031)

摘　　要：目的:探讨氧化应激对冠状动脉慢血流现象(CSFP)的影响。方法:选取冠状动脉(冠脉)造影显示心外膜冠脉无明显病变的慢血流的患者35例,为CSFP组;另选取同期因心脏症状行冠脉造影显示冠脉正常的患者35例,为对照组。对两组患者分别检测氧化应激指标过氧化氢酶(CAT)、超氧物歧化酶(SOD)、丙二醛(MDA)、异构前列腺素及缺血修饰白蛋白的水平。结果:CSFP组的CAT(6.53±2.2)U/ml、SOD(1.12±0.11)U/ml明显低于对照组CAT(17.87±5.74)U/ml、SOD(1.22±0.14)U/ml,而MDA(4.96±1.27)nmol/ml、8-isoPGF2α(77.1±35.49)pg/ml水平明显高于对照组MDA(3.93±0.91)nmol/ml、8-iso-PGF2α(59.75±17.47)pg/ml;同时在校正患者年龄、性别、吸烟及体重后,经Logistic多因素回归分析发现,MDA及8-iso-PGF2α是CSFP的危险因素,而SOD、CAT则是CSFP的保护因素。结论:CSFP患者MDA、8-iso-PGF2α明显上升,CAT、SOD明显下降,提示氧化应激可能在CSFP的病理生理方面有重要的作用。Objective：To explore the influences of oxidative stress on coronary slow flow phenomenon.Method：we enrolled 35 patients with normal epicardial coronary artery proven by coronary arteriography as the CSFP group,and another 35 subjects which had normal coronary angiography as the control group.We measured plasma CAT,SOD,MDA,heterogeneous prostaglandins and albumin levels in these patients and control subjects.Result：We found that CAT（6.53±2.2U/ml）and SOD（1.12±0.11U/ml）levels was significantly lower in CSFP compared to the control group CAT（17.87±5.74 U/ml）,SOD（1.22±0.14 U/ml）,while MDA（4.96±1.27nmol/ml）,8-iso-PGF2α（77.1±35.49pg/ml）levels was significantly higher in CSFP compared to the control group MDA（3.93±0.91nmol/ml）,8-iso-PGF2α（59.75±17.47pg/ml）.After adjustment for age,sex,smoking and weight,Logistic regression analysis showed that MDA and 8-iso-PGF2αis a risk factor of CSFP,while the SOD and CAT were the protection of the CSFP factors.Conclusion：The MDA,8-iso-PGF2αalpha levles were significantly higher in CSFP patients,while CAT and SOD were significantly lower compared to the control group.Oxidative stress plays a key role in the pathophysiology of CSFP.

关 键 词：冠状动脉慢血流 过氧化氢酶 超氧物歧化酶 丙二醛 异构前列腺素 缺血修饰白蛋白 氧化应激 

分 类 号：R544.1[医药卫生—心血管疾病]